IMDC Risk Model for Metastatic Renal Cell Carcinoma Clinical Calculator and Pathways - Guideline Central

IMDC Risk Model for Metastatic Renal Cell Carcinoma

Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria).

<1 year from time of diagnosis to systemic therapy

Karnofsky Performance Status <80%

Hemoglobin < lower limit of normal

  • Usually ~120 g/L or 12 g/dL

Corrected calcium > upper limit of normal

  • Usually ~120 g/L or 12 g/dL

Neutrophils > upper limit of normal

  • Usually ~2.0-7.0ₓ109/L

Platelets > upper limit of normal

  • Usually ~150,000-400,000 cells/µL

Interpretation

Source: Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO. Dec 1, 2009:5794-5799; published online on October 13, 2009.
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.